Press Release: Basilea provides corporate update -2-

5. T. Helsten, S. Elkin, E. Arthur et al. The FGFR landscape in cancer:

Analysis of 4,853 tumors by next-generation sequencing. Clinical Cancer

Research 2016 (22), 259-267

6. P. McSheehy, F. Bachmann, N. Forster-Gross et al. Derazantinib (DZB): A

dual FGFR/CSF1R-inhibitor active in PDX-models of urothelial cancer.

Molecular Cancer Therapeutics 2019 (18), 12 supplement, pp. LB-C12

7. M. A. Cannarile, M. Weisser, W. Jacob et al. Colony-stimulating factor 1

receptor (CSF1R) inhibitors in cancer therapy. Journal for ImmunoTherapy

of Cancer 2017, 5:53

8. Y. Zhu, B. L. Knolhoff, M. A. Meyer et al. CSF1/CSF1R Blockade reprograms

tumor-infiltrating macrophages and improves response to T cell checkpoint

immunotherapy in pancreatic cancer models. Cancer Research 2014 (74),

5057-5069

9. E. Peranzoni, J. Lemoine, L. Vimeux et al. Macrophages impede CD8 T cells

from reaching tumor cells and limit the efficacy of anti--PD-1 treatment.

Proceedings of the National Academy of Science of the United States of

America 2018 (115), E4041-E4050

10. V. Mazzaferro, B. F. El-Rayes, M. Droz dit Busset et al. Derazantinib

(ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive

intrahepatic cholangiocarcinoma. British Journal of Cancer 2019 (120),

165-171. ClinicalTrials.gov identifier: NCT01752920

11. ClinicalTrials.gov identifier: NCT03230318

12. ClinicalTrials.gov identifier: NCT04045613. Tecentriq(R) is a registered

trademark of Hoffmann-La Roche Ltd.

13. J. Pohlmann, F. Bachmann, A. Schmitt-Hoffmann et al. BAL101553: An

optimized prodrug of the microtubule destabilizer BAL27862 with superior

antitumor activity. American Association for Cancer Research (AACR)

annual meeting 2011, abstract 1347; Cancer Research 2011, 71 (8

supplement)

14. ClinicalTrials.gov identifier: NCT02490800

15. ClinicalTrials.gov identifier: NCT03250299

16. ClinicalTrials.gov identifier: NCT02895360

17. A. Sharmq, A. Broggini-Tenzer, V. Vuong et al. The novel microtubule

targeting agent BAL101553 in combination with radiotherapy in

treatment-refractory tumor models. Radiotherapy Oncology 2017 (124),

433-438

18. G. E. Duran, H. Lane, F. Bachmann et al. In vitro activity of the novel

tubulin active agent BAL27862 in MDR1(+) and MDR1(-) human breast and

ovarian cancer variants selected for resistance to taxanes. American

Association for Cancer Research (AACR) annual meeting 2010, abstract

4412; Cancer Research 2010, 70 (8 supplement)

19. F. Bachmann, K. Burger, G. E. Duran et al. BAL101553 (prodrug of

BAL27862): A unique microtubule destabilizer active against drug

refractory breast cancers alone and in combination with trastuzumab.

American Association for Cancer Research (AACR) annual meeting 2014,

abstract 831; Cancer Research 2014, 74 (19 supplement)

20. A. Schmitt-Hoffmann, D. Klauer, K. Gebhardt et al. BAL27862: a unique

microtubule-targeted agent with a potential for the treatment of human

brain tumors. AACR-NCI-EORTC conference 2009, abstract C233; Molecular

Cancer Therapeutics 2009, 8 (12 supplement)

21. A. C. Mladek, J. L. Pokorny, H. Lane et al. The novel tubulin-binding

'tumor checkpoint controller' BAL101553 has anti-cancer activity alone

and in combination treatments across a panel of GBM patient-derived

xenografts. American Association for Cancer Research (AACR) annual

meeting 2016, abstract 4781; Cancer Research 2016, 76 (14 supplement)

22. R. Bergès, A. Tchoghandjian, S. Honoré et al. The novel

tubulin-binding checkpoint activator BAL101553 inhibits EB1-dependent

migration and invasion and promotes differentiation of glioblastoma

stem-like cells. Molecular Cancer Therapeutics 2016 (15), 2740-2749

23. A. E. Prota, F. Danel, F. Bachmann et al. The novel

microtubule-destabilizing drug BAL27862 binds to the colchicine site of

tubulin with distinct effects on microtubule organization. Journal of

Molecular Biology 2014 (426), 1848-1860

24. F. Bachmann, K. Burger, H. Lane. BAL101553 (prodrug of BAL27862): the

spindle assembly checkpoint is required for anticancer activity. American

Association for Cancer Research (AACR) annual meeting 2015, abstract

3789; Cancer Research 2015, 75 (15 supplement)

Attachments

-- Press release (PDF).pdf

https://ml-eu.globenewswire.com/Resource/Download/e4f177c7-3cc6-4506-b912-69eb84d2bc9a

(END) Dow Jones Newswires

May 28, 2020 01:15 ET (05:15 GMT)